Skip to main content
. Author manuscript; available in PMC: 2019 Jan 24.
Published in final edited form as: Int J Dermatol. 2017 Mar 21;56(8):833–835. doi: 10.1111/ijd.13598

Table 1.

Hematologic parameters throughout ruxolitinib treatment

0 months 1 month 3 months 6 months 12 months
Patient 1
 Hemoglobin (g/dl)/Hematocrit (%)  14.2/42.6  13.9/41.0  12.4/37.5  12.5/38.5  12.4/37.2
 Leukocytes (103/ul)   9.1   5.4   6.6   5.6   5.9
 Platelets (103/ul) 345 365 391 387 403
Patient 2
 Hemoglobin (g/dl)/Hematocrit (%)  10.9/34.2  11.6/36.3  12.2/36.2  11.6/34.8  11.6/34.6
 Leukocytes (103/ul)   6.3   6.4   4.6   5.5   6.2
 Platelets (103/ul) 276 279 293 327 332